Insider Trading Alert - CFN, ANF And VRSN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 4, 2014, 177 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,320.24 to $419,318,750.00.

Highlighted Stocks Traded by Insiders:

CareFusion (CFN) - FREE Research Report

Leonard Thomas J who is President, Medical Systems at CareFusion sold 1,250 shares at $40.26 on March 4, 2014. Following this transaction, the President, Medical Systems owned 37,053 shares meaning that the stake was reduced by 3.26% with the 1,250-share transaction.

Abbey Donald who is EVP, Quality Reg & Med Affairs at CareFusion sold 6,000 shares at $41.02 on March 4, 2014. Following this transaction, the EVP, Quality Reg & Med Affairs owned 28,143 shares meaning that the stake was reduced by 17.57% with the 6,000-share transaction.

The shares most recently traded at $41.05, up $0.03, or 0.07% since the insider transaction. Historical insider transactions for CareFusion go as follows:

  • 4-Week # shares sold: 12,000
  • 12-Week # shares sold: 59,746
  • 24-Week # shares sold: 98,496

The average volume for CareFusion has been 1.6 million shares per day over the past 30 days. CareFusion has a market cap of $8.4 billion and is part of the health care sector and health services industry. Shares are up 1.05% year-to-date as of the close of trading on Tuesday.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. The company has a P/E ratio of 23.9. Currently there are 5 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFN - FREE

TheStreet Quant Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Abercrombie & Fitch Company (ANF) - FREE Research Report

Jeffries Michael S who is Ceo at Abercrombie & Fitch Company sold 50,000 shares at $39.26 on March 4, 2014. Following this transaction, the Ceo owned 957,728 shares meaning that the stake was reduced by 4.96% with the 50,000-share transaction.

The shares most recently traded at $41.68, up $2.42, or 5.8% since the insider transaction. Historical insider transactions for Abercrombie & Fitch Company go as follows:

  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 16,710

The average volume for Abercrombie & Fitch Company has been 3.1 million shares per day over the past 30 days. Abercrombie & Fitch Company has a market cap of $3.0 billion and is part of the services sector and retail industry. Shares are up 19.33% year-to-date as of the close of trading on Tuesday.

Abercrombie & Fitch Co., through its subsidiaries, operates as a specialty retailer of casual apparel for men, women, and kids. It operates through three segments: U.S. Stores, International Stores, and Direct-to-Consumer. The stock currently has a dividend yield of 2.04%. The company has a P/E ratio of 56.9. Currently there are 10 analysts that rate Abercrombie & Fitch Company a buy, 2 analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANF - FREE

TheStreet Quant Ratings rates Abercrombie & Fitch Company as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Abercrombie & Fitch Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

VeriSign (VRSN) - FREE Research Report

Roach John D who is Director at VeriSign sold 333 shares at $54.71 on March 4, 2014. Following this transaction, the Director owned 12,346 shares meaning that the stake was reduced by 2.63% with the 333-share transaction.

The shares most recently traded at $56.64, up $1.93, or 3.41% since the insider transaction. Historical insider transactions for VeriSign go as follows:

  • 4-Week # shares sold: 333
  • 12-Week # shares sold: 666
  • 24-Week # shares sold: 666

The average volume for VeriSign has been 1.9 million shares per day over the past 30 days. VeriSign has a market cap of $7.4 billion and is part of the technology sector and internet industry. Shares are down 7.68% year-to-date as of the close of trading on Tuesday.

VeriSign, Inc. provides Internet infrastructure services to various networks worldwide. The company offers domain name registry services that operate the authoritative directory of .com, .net, .cc, .tv, and .name domains, as well as the back-end systems for various.gov, .jobs, and .edu domains. The company has a P/E ratio of 15.8. Currently there are 2 analysts that rate VeriSign a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRSN - FREE

TheStreet Quant Ratings rates VeriSign as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, compelling growth in net income, revenue growth, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full VeriSign Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers